IOVA
Iovance Biotherapeutics Inc.
$2.05
-$0.15(-6.82%)
36
Overall
--
Value
45
Tech
28
Quality
Market Cap
$741.80M
Volume
23.09M
52W Range
$1.64 - $12.51
Target Price
$9.10
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | -- | -- | -- | -- | -- | -- | -- | -- | $1.2M | $164.1M | ||
| Total Revenue | -- | -- | -- | -- | -- | -- | -- | -- | $1.2M | $164.1M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-3.8M | -- | -- | -- | -- | -- | -- | -- | $10.8M | $124.0M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $3.8M | -- | -- | -- | -- | -- | -- | -- | $-9.6M | $40.1M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-27.9M | $-53.6M | $-92.9M | $128.3M | $206.9M | $261.9M | $342.7M | $398.9M | $451.0M | $435.4M | ||
| Research & Development | $15.5M | $26.9M | $71.6M | $99.8M | $166.0M | $201.7M | $259.0M | $294.8M | $344.1M | $282.3M | ||
| Research Expense | $15.5M | $26.9M | $71.6M | $99.8M | $166.0M | $201.7M | $259.0M | $294.8M | $344.1M | $282.3M | ||
| Selling, General & Administrative | $12.4M | $26.7M | $21.3M | $28.4M | $40.8M | $60.2M | $83.7M | $104.1M | $106.9M | $153.0M | ||
| General & Administrative Expenses | $12.4M | $26.7M | $21.3M | $28.4M | $40.8M | $60.2M | $83.7M | $104.1M | $106.9M | $153.0M | ||
| Salaries & Wages | $-8.5M | $-18.9M | $-12.0M | $-20.0M | $24.3M | $40.9M | $69.8M | -- | -- | $109.6M | ||
| Depreciation & Amortization | $-1.0M | $-1.0M | $-1.0M | $-1.0M | $1.2M | $1.1M | $3.1M | $9.3M | $11.6M | $12.0M | ||
| Depreciation & Amortization | $-1.0M | $-1.0M | $-1.0M | $-1.0M | $1.2M | $1.1M | $3.1M | -- | -- | $12.0M | ||
| Amortization | -- | -- | -- | -- | -- | -- | -- | -- | $9.8M | $21.3M | ||
| Other Operating Expenses | -- | -- | $-1.3M | $-2.1M | $-3.7M | $-4.4M | $-3.9M | -- | -- | $-3.7M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-27.9M | $-53.6M | $-92.9M | $-128.3M | $-206.9M | $-261.9M | $-342.7M | $-398.9M | $-460.6M | $-395.3M | ||
| EBITDA | $-26.7M | $-52.0M | $-91.1M | $-124.0M | $-199.8M | $-253.2M | $-328.7M | $-374.8M | $-414.4M | $-331.3M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Intinc | $200.0K | $745.0K | $813.0K | $4.7M | $9.3M | $2.4M | $451.0K | $3.0M | $13.0M | $20.3M | ||
| Net Non-Operating Interest Income/Expense | $200.0K | $745.0K | $813.0K | $4.7M | $9.3M | $2.4M | $451.0K | $3.0M | $13.0M | $20.3M | ||
| Gain on Sale of Securities | -- | $32.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | -- | $-32.0K | -- | -- | $-12.3M | -- | -- | -- | -- | $1.8M | ||
| Other Special Charges | -- | -- | -- | -- | $12.3M | -- | -- | -- | -- | -- | ||
| SPECIAL ITEMS | ||||||||||||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | $7.4M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-27.7M | $-52.9M | $-92.1M | $-123.6M | $-197.6M | $-261.9M | $-342.7M | $-395.9M | $-447.5M | $-375.0M | ||
| Pre-Tax Income | $-27.7M | $-52.9M | $-92.1M | $-123.6M | $-197.6M | $-259.6M | $-342.3M | $-395.9M | $-447.5M | $-375.0M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | -- | $-1.3M | $-223.0K | $-47.0M | $-59.9M | -- | -- | $-3.5M | $-2.8M | ||
| NET INCOME | ||||||||||||
| Net Income | $-27.7M | $-52.9M | $-92.1M | $-123.6M | $-197.6M | $-259.6M | $-342.3M | $-395.9M | $-444.0M | $-372.2M | ||
| Net Income (Continuing Operations) | $-27.7M | $-52.9M | $-92.1M | $-123.6M | $-197.6M | $-259.6M | $-342.3M | $-395.9M | $-444.0M | $-372.2M | ||
| Net Income (Discontinued Operations) | $-27.7M | $-52.9M | $-92.1M | $-123.6M | $-197.6M | $-259.6M | $-342.3M | $-395.9M | $-444.0M | $-372.2M | ||
| Net Income (Common Stockholders) | $-27.7M | $-102.3M | $-92.1M | $-123.6M | $-197.6M | $-259.6M | $-342.3M | $-395.9M | $-444.0M | $-372.2M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-376.0M | ||
| TOTALS | ||||||||||||
| Total Expenses | $27.9M | $-53.6M | $-92.9M | $128.3M | $206.9M | $261.9M | $342.7M | $398.9M | $461.7M | $559.3M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $44.4K | $55.3K | $65.2K | $97.3K | $124.3K | $138.3K | $153.4K | $159.3K | $235.1K | $289.9K | ||
| Average Shares Outstanding (Diluted) | $44.6M | $28.6M | $65.3M | $97.3K | $124.3K | $138.3K | $153.4K | $159.3K | $235.1K | $289.9K | ||
| Shares Outstanding | $48.6M | $62.3M | $89.4M | $123.4M | $126.5M | $147.0M | $157.2M | $224.2M | $279.3M | $327.9M | ||
| Basic EPS | -- | -- | -- | -- | $-1.59 | $-1.88 | $-2.23 | $-2.49 | $-1.89 | $-1.28 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-1.59 | $-1.88 | $-2.23 | $-2.49 | $-1.89 | $-1.28 | ||
| Diluted EPS | $-0.62 | $-1.85 | $-1.41 | $-1.27 | $-1.59 | $-1.88 | $-2.23 | $-2.49 | $-1.89 | $-1.28 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $-1.27 | -- | -- | $-2.23 | $-2.49 | $-1.89 | $-1.28 | ||
| OTHER METRICS | ||||||||||||
| Accrued Preferred Stock Dividends | -- | $49.5M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Gain On Sale Of P P E | -- | -- | -- | -- | -- | -- | -- | -- | -- | $5.6M | ||
| Net Operating Interest Income Expense | $200.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $12.4M | $26.7M | $21.3M | $28.4M | $40.8M | $60.2M | $83.7M | $104.1M | $106.9M | $153.0M | ||
| Otherunder Preferred Stock Dividend | -- | $49.5M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Preferred Stock Dividends | -- | $49.5M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $12.4M | $26.7M | $21.3M | $-1.0M | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IOVA | $2.05 | -6.8% | 23.09M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Iovance Biotherapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW